NYSE: LINLinde Plc Stock
LIN Price
$253.12
Fair Value Price
$262.95
Market Cap
$132.98B
52 Week Low
$146.71
52 Week High
$274.58
P/E
59.98x
P/B
2.88x
P/S
4.63x
PEG
1.59x
Dividend Yield
1.49%
Revenue
$27.05B
Earnings
$2.24B
Gross Margin
42.8%
Operating Margin
11.41%
Profit Margin
8.3%
Debt to Equity
0.84
Operating Cash Flow
$7B
Beta
0.95
Next Earnings
Feb 5, 2021
Ex-Dividend
N/A
Next Dividend
N/A
LIN Overview
Zen Score
High
Medium
Low
35
Industry average
Reasons for this score
LIN ($253.12) is undervalued by 3.74% relative to our estimate of its Fair Value price of $262.95 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Valuation
LIN ($253.12) is trading below its intrinsic value of $561.37, according to Benjamin Graham's Formula from Chapter 14 of "The Intelligent Investor"
Valuation
LIN is poor value based on its earnings relative to its share price (59.98x), compared to the US market average (31.52x)
Valuation
LIN News
Valuation
LIN fair value
Fair Value of LIN stock based on Discounted Cash Flow (DCF)
LIN ($253.12) is undervalued by 3.74% relative to our estimate of its Fair Value price of $262.95 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Valuation
LIN ($253.12) is trading below its intrinsic value of $561.37, according to Benjamin Graham's Formula from Chapter 14 of "The Intelligent Investor"
Valuation
LIN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
59.98x
Industry
36.18x
Market
31.52x
LIN is poor value based on its earnings relative to its share price (59.98x), compared to the US market average (31.52x)
Valuation
LIN is poor value based on its earnings relative to its share price (59.98x), compared to the US Specialty Chemicals industry average (36.18x)
Valuation
LIN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.88x
Industry
6.48x
Market
56.65x
LIN is good value based on its book value relative to its share price (2.88x), compared to the US market average (56.65x)
Valuation
LIN is good value based on its book value relative to its share price (2.88x), compared to the US Specialty Chemicals industry average (6.48x)
Valuation
LIN price to earnings growth (PEG)
For valuing profitable companies with growth potential
LIN is poor value relative to its rate of earnings growth, measured by PEG ratio (1.59x)
Valuation
LIN's financial health
Profit margin
Revenue
$6.9B
Net Income
$700.0M
Profit Margin
10.2%
LIN's Earnings (EBIT) of $3.09B can safely cover interest payments on company debt ($17.80B)
Financials
LIN's profit margin has decreased (-9.3%) in the last year from (17.6%) to (8.3%)
Financials
Assets to liabilities
Assets
$87.2B
Liabilities
$38.6B
Debt to equity
0.39
LIN's short-term liabilities ($14.79B) exceed its short-term assets ($12.27B)
Financials
LIN's long-term liabilities ($23.83B) exceed its short-term assets ($12.27B)
Financials
LIN's debt to equity ratio (0.84) is considered high
Financials
Cash flow
Operating
$1.9B
Investing
-$732.0M
Financing
-$933.0M
LIN's operating cash flow ($7.17B) is sufficient to service the company's debt ($17.80B)
Financials
Linde Stock FAQ
©2021 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
